Benzyl 3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate | 1375090-16-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Benzyl 3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
• 英文别名: benzyl 3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
• CAS: 1375090-16-6
• 化学式: C₁₆H₂₃NO₅
• 分子量: 309.362
• InChiKey: WLJVLKJKMIFSHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Benzyl 3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate 生成 benzyl O-methyl-L-serinate 2,2,2-trifluoroacetate
  参考文献：
  名称：

  Crystalline tripeptide epoxy ketone protease inhibitors

  摘要：

  本发明涉及晶体三肽酮环氧化合物、其制备方法及相关药物组合物。

  公开号：

  US09403868B2
• 作为产物：
  描述：

  保护的甲基-L-丝氨酸二环己基铵盐 以88的产率得到Benzyl 3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
  参考文献：
  名称：

  Crystalline tripeptide epoxy ketone protease inhibitors

  摘要：

  本发明涉及晶体三肽酮环氧化合物、其制备方法及相关药物组合物。

  公开号：

  US09403868B2

文献信息

• Process for the preparation of Lacosamide including resolution of O-methyl-DL-serine
  申请人：UCB Pharma GmbH

  公开号：EP2487152A1

  公开（公告）日：2012-08-15

  The present invention provides a process for the preparation of lacosamide in substantially optically pure form, which in one aspect comprises the following steps: (i) resolution of O-methyl-D,L-serine to provide O-methyl-D-serine in substantially optically pure form; (ii) acetylation of O-methyl-D-serine thereby obtained to provide the N-acetyl derivative thereof in substantially optically pure form; (iii) activating the carboxy group of the compound thereby obtained; and (iv) reacting the compound thereby obtained with benzylamine.

  本发明提供了一种制备几乎光学纯度的拉科萨米德的方法，其中一方面包括以下步骤：(i) 分离O-甲基-D，L-丝氨酸以提供几乎光学纯度的O-甲基-D-丝氨酸；(ii) 乙酰化由此得到的O-甲基-D-丝氨酸，以提供几乎光学纯度的其N-乙酰衍生物；(iii) 激活所得化合物的羧基；和 (iv) 用苄胺与所得化合物反应。
• [EN] PROCESS FOR PREPARING LACOSAMIDE<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN LACOSAMIDE
  申请人：UCB PHARMA GMBH

  公开号：WO2012065891A1

  公开（公告）日：2012-05-24

  The present invention provides a process for the preparation of lacosamide in substantially optically pure form, which in one aspect comprises the following steps: (i) resolution of O-methyl-D,L-serine to provide O-methyl-D-serine in substantially optically pure form; (ii) acetylation of O-methyl-D-serine thereby obtained to provide the N-acetyl 10 derivative thereof in substantially optically pure form; (iii) activating the carboxy group of the compound thereby obtained; and (iv) reacting the compound thereby obtained with benzylamine.

  本发明提供一种制备几乎光学纯度的拉科萨米德的方法，其中一方面包括以下步骤：(i)分离O-甲基-D，L-丝氨酸以提供几乎光学纯度的O-甲基-D-丝氨酸；(ii)乙酰化因此获得的O-甲基-D-丝氨酸，以提供几乎光学纯度的N-乙酰基10衍生物；(iii)激活所获得化合物的羧基；以及(iv)将所获得的化合物与苄基胺反应。
• Crystalline tripeptide epoxy ketone protease inhibitors
  申请人：Onyx Therapeutics, Inc.

  公开号：US09403868B2

  公开（公告）日：2016-08-02

  The invention relates to crystalline tripeptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions.

  本发明涉及晶体三肽酮环氧化合物、其制备方法及相关药物组合物。
• FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS
  申请人：FLUORINOV PHARMA INC.

  公开号：US20150203534A1

  公开（公告）日：2015-07-23

  The present application relates to novel fluorinated epoxyketone-based compounds, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions mediated by proteasome inhibition, in particular, the present application includes compounds of Formula I, and compositions and uses thereof:

  本申请涉及新型氟代环氧酮基化合物，包括这些化合物的组合物和它们的用途，特别是用于治疗由蛋白酶体抑制介导的疾病、紊乱或病况，特别是本申请包括公式I的化合物，以及它们的组合物和用途：
• KETOAMIDE IMMUNOPROTEASOME INHIBITORS
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20150274777A1

  公开（公告）日：2015-10-01

  The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein X, R 1 , R 1′ , R 2 , R 2′ , R 3 , R 4 , R 4′ and R 5 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.

  本发明涉及式(I)的化合物及其药学上可接受的盐，其中X、R1、R1'、R2、R2'、R3、R4、R4'和R5在详细说明书和权利要求中有定义。此外，本发明还涉及制造和使用式(I)化合物的方法，以及含有这种化合物的药物组合物。式(I)化合物是LMP7抑制剂，可能有用于治疗相关的炎症性疾病和疾病，例如类风湿性关节炎、狼疮和肠易激综合症。